Novo Nordisk Acquires Forma Therapeutics

BioSelective Capital Investments Acquires BioDuro's Irvine Drug Product Operations to Form Forma Life Sciences

February 4, 2026

Pharmaceuticals

BioSelective Capital Investments, together with Shayan Enterprises, LLC, acquired BioDuro’s drug product development and manufacturing operations in Irvine, California and formed Forma Life Sciences, Inc. The transaction transfers two U.S.-based oral solid dosage development and manufacturing facilities (≈65,000 sq ft and ≈40,000 sq ft) to the new Delaware-held company; BioDuro (an Advent portfolio company) sold the assets.

Novo Nordisk to Acquire Akero Therapeutics for Up to $5.2 Billion

October 10, 2025

Pharmaceuticals

Akero Therapeutics announced it has entered into a definitive agreement to be acquired by Novo Nordisk A/S in a transaction valued at up to $5.2 billion in cash. Under the terms of the deal, Akero shareholders will receive $54.00 per share at closing plus a non-transferable Contingent Value Right (CVR) that could pay an additional $6.00 per share contingent on full U.S. regulatory approval of efruxifermin (EFX) for compensated cirrhosis associated with MASH.

Novartis to Acquire MorphoSys in $2.9 Billion Deal

February 7, 2024

Pharmaceuticals

Novartis agreed to a voluntary public takeover offer to acquire MorphoSys AG for €68 per share, valuing the deal at about €2.7 billion (reported as $2.9 billion). The acquisition is intended to expand and complement Novartis’ oncology pipeline, including pelabresib (CPI-0610) and tulmimetostat (CPI-0209).

Novo Nordisk to Acquire Dicerna Pharmaceuticals (GalXC RNAi Platform)

November 18, 2021

Biotechnology

Novo Nordisk entered into a definitive agreement to acquire Dicerna Pharmaceuticals for $38.25 per share in cash, valuing the deal at approximately $3.3 billion. The acquisition expands Novo Nordisk’s RNAi research technology platform, building on a 2019 research collaboration using Dicerna’s GalXC technology.

Novartis Acquires Regulus Therapeutics

June 25, 2025

Biotechnology

Novartis has completed the acquisition of Regulus Therapeutics, making Regulus an indirect wholly owned subsidiary following a tender offer and merger. The deal secures Regulus' investigational oligonucleotide therapy farabursen for ADPKD and strengthens Novartis' renal disease pipeline.

CSL Limited Acquires Vifor Pharma Ltd in All-Cash Tender Offer

December 14, 2021

Pharmaceuticals

CSL Limited entered into a definitive agreement to acquire Vifor Pharma Ltd via an all-cash public tender offer at US$179.25 per share (aggregate equity value about US$11.7 billion). The transaction was funded through a mix of placement, new debt, and existing cash/facilities and was expected to complete around mid-2022, subject to regulatory approvals.